Published in Clin Cancer Res on June 03, 2014
Trametinib With GSK2141795 in BRAF Wild-type Melanoma | NCT01941927
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer. Oncotarget (2015) 1.06
Molecular therapy for acute myeloid leukaemia. Nat Rev Clin Oncol (2015) 0.86
Treatment of NRAS-mutant melanoma. Curr Treat Options Oncol (2015) 0.86
Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biol Ther (2015) 0.80
Simple, Sensitive and Accurate Multiplex Detection of Clinically Important Melanoma DNA Mutations in Circulating Tumour DNA with SERS Nanotags. Theranostics (2016) 0.79
Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin. PLoS One (2016) 0.76
Key drivers of biomedical innovation in cancer drug discovery. EMBO Mol Med (2014) 0.75
Effects of miR-145-5p through NRAS on the cell proliferation, apoptosis, migration, and invasion in melanoma by inhibiting MAPK and PI3K/AKT pathways. Cancer Med (2017) 0.75
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48
RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer (2011) 6.45
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet (2008) 5.07
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res (2006) 4.29
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev (1997) 4.24
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Identification of transforming gene in two human sarcoma cell lines as a new member of the ras gene family located on chromosome 1. Nature (1983) 3.86
Human RAS superfamily proteins and related GTPases. Sci STKE (2004) 3.80
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol (2004) 3.56
Three human transforming genes are related to the viral ras oncogenes. Proc Natl Acad Sci U S A (1983) 3.06
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov (2007) 2.67
Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol (2001) 2.60
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov (2013) 2.43
Induction of cyclin D1 overexpression by activated ras. Oncogene (1994) 2.35
Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med (2012) 2.26
Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One (2009) 2.07
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res (2006) 1.85
Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene (2008) 1.79
Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res (1996) 1.74
Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol (2001) 1.73
A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice. Sci Transl Med (2011) 1.72
Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. Nature (2009) 1.72
Targeting oncogenic Ras signaling in hematologic malignancies. Blood (2012) 1.67
Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia (2010) 1.65
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. Pigment Cell Melanoma Res (2013) 1.56
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52
Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci U S A (1994) 1.52
Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol (2004) 1.46
First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res (2012) 1.39
NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol (2010) 1.38
The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma. Clin Cancer Res (2013) 1.38
RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia (2004) 1.38
Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer (2005) 1.37
Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. Cancer (2012) 1.32
Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. Cancer Res (2013) 1.19
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin Cancer Res (2013) 1.19
Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother (2012) 1.18
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene (2012) 1.15
Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene (2010) 1.13
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol (2013) 1.12
Targeting NRAS in melanoma. Cancer J (2012) 1.00
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J Transl Med (2012) 0.97
Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation. Cell Cycle (2012) 0.94
Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. Leukemia (2011) 0.92
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. Mol Cancer Ther (2013) 0.88
A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia. Leukemia (2011) 0.85
Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11. Pigment Cell Melanoma Res (2012) 0.84